Inclisiran
http://dbpedia.org/resource/Inclisiran an entity of type: Thing
Inclisiran (Handelsname Leqvio) ist ein Arzneistoff zur Behandlung erhöhter Cholesterinspiegel (Hypercholesterinämie) oder der gemischten Dyslipidämie (Fettstoffwechselstörung einhergehend mit zu hohen Spiegeln von Lipiden wie Cholesterin und Triglyzeriden oder beidem). Es gehört zur Gruppe der RNAi-Therapeutika.
rdf:langString
L'inclisiran est un petit ARN interférent dirigé contre l'ARN du PCSK9, en cours de test dans les hypercholestérolémies.
rdf:langString
Inclisiran, commercializzato con il nome Leqvio, è un farmaco per la riduzione effiace e sostenuta nel tempo del colesterolo LDL. Inclisiran è indicato il trattamento della malattia cardiovascolare aterosclerotica e dell'ipercolesterolemia familiare eterozigote in aggiunta al controllo dietetico e a una statina o in alternativa alle statine laddove esse siano controindicate o non tollerate. Si tratta del primo siRNA che riduce la traduzione della proteina PCSK9. LEQVIO è commercializzato in Europa da Novartis.
rdf:langString
Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.
rdf:langString
rdf:langString
Inclisiran
rdf:langString
Inclisiran
rdf:langString
Inclisiran
rdf:langString
Inclisiran
xsd:integer
55572620
xsd:integer
1107260491
rdf:langString
AX16
rdf:langString
secondary source-derived descriptions of the class of this agent, information on its discovery, and its mechanism of action
<nicaraguanCórdoba>
10.0
xsd:integer
520
xsd:integer
1639324
xsd:integer
176399
rdf:langString
August 2022
rdf:langString
DB14901
xsd:integer
21
xsd:integer
679
rdf:langString
D11931
rdf:langString
Rx-only
xsd:integer
175
xsd:integer
309
xsd:integer
43
xsd:integer
6
rdf:langString
no
rdf:langString
ALN-PCSsc, ALN-60212
rdf:langString
Leqvio
rdf:langString
UOW2C71PG5
rdf:langString
Inclisiran (Handelsname Leqvio) ist ein Arzneistoff zur Behandlung erhöhter Cholesterinspiegel (Hypercholesterinämie) oder der gemischten Dyslipidämie (Fettstoffwechselstörung einhergehend mit zu hohen Spiegeln von Lipiden wie Cholesterin und Triglyzeriden oder beidem). Es gehört zur Gruppe der RNAi-Therapeutika.
rdf:langString
Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9. Inclisiran was approved for use in the European Union in December 2020. In August 2021, it received NICE approval for use by the National Health Service in the UK. In December 2021, it was approved for medical use in the United States.
rdf:langString
L'inclisiran est un petit ARN interférent dirigé contre l'ARN du PCSK9, en cours de test dans les hypercholestérolémies.
rdf:langString
Inclisiran, commercializzato con il nome Leqvio, è un farmaco per la riduzione effiace e sostenuta nel tempo del colesterolo LDL. Inclisiran è indicato il trattamento della malattia cardiovascolare aterosclerotica e dell'ipercolesterolemia familiare eterozigote in aggiunta al controllo dietetico e a una statina o in alternativa alle statine laddove esse siano controindicate o non tollerate. Si tratta del primo siRNA che riduce la traduzione della proteina PCSK9. LEQVIO è commercializzato in Europa da Novartis.
rdf:langString
Inclisiran
rdf:langString
S4
rdf:langString
Rx-only
rdf:langString
Rx-only
rdf:langString
B1
xsd:nonNegativeInteger
15831
rdf:langString
Leqvio
xsd:string
1639324-58-5
xsd:string
176399
xsd:string
DB14901
xsd:string
UOW2C71PG5
xsd:string
D11931